The OncAlert™ Oral Cancer product line is transforming detection and improving outcomes through simple, accurate, and cost-effective solutions for the early detection and intervention of oral cancer.
The OncAlert Oral Cancer LAB Test (“OncAlert LAB Test”) and the the OncAlert Oral Cancer RAPID Test (“OncAlert RAPID Test”) are the first and only commercially-available technologies that measure an unprecedented combination of soluble CD44, a tumor-initiating and stem cell associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. Both products use a simple, oral rinse collection and measurement procedure that is easy to administer and non-invasive for the patient.
The solution leverages an innovative, patented technology that detects specific protein markers known to indicate possible presence of oral cancer, even prior to observation of visual or physical symptoms. The simple oral rinse procedure is easy to administer and non-invasive for the patient.
The OncAlert™ Oral Cancer LAB Test and the OncAlert™ Oral Cancer RAPID Test are CE Marked and available for sale in select international markets. The OncAlert™ product line is not yet available for sale in the United States at this time.